Evidence map›Paper›PMID 28671997›Full record

ArticlePloS one2017

Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats.

Douglas M Bennion, Jacob D Isenberg, Allison T Harmel, Kelly DeMars, Alex N Dang, Chad H Jones, Megan E Pignataro, Justin T Graham, U Muscha Steckelings, Jon C Alexander and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. The Angiotensin ATPharmacological reviews · 2022
    Review
  4. Review
  5. Review
  6. Review
  7. Angiotensin ATJournal of neuroinflammation · 2020
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Douglas M BennionDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.ORCID http://orcid.org/0000-0003-3394-7164
Jacob D IsenbergDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Allison T HarmelDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Kelly DeMarsDepartment of Neuroscience and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Alex N DangDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Chad H JonesDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Megan E PignataroDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Justin T GrahamDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
U Muscha SteckelingsDepartment of Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.
Jon C AlexanderDepartment of Psychiatry and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Marcelo FeboDepartment of Psychiatry and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Eric G KrauseDepartment of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Florida, United States of America.
Annette D de KloetDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Eduardo Candelario-JalilDepartment of Neuroscience and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Colin SumnersDepartment of Physiology and Functional Genomics and McKnight Brain Institute, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
University of Florida · USUniversity of Southern Denmark · DK

Funding

Multidisciplinary Training Program in HypertensionT32HL083810 · NHLBI · UNIVERSITY OF FLORIDA · PI WOOD, CHARLES E · 2007 to 2017
$2.5M
Cyclooxygenase-2 Regulation of Blood-Brain Barrier Opening in Ischemic StrokeR01NS065849 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CANDELARIO-JALIL, EDUARDO JESUS · 2011 to 2015
$1.5M
Neurovascular Protection by Adropin in Ischemic StrokeR56NS103094 · NINDS · UNIVERSITY OF FLORIDA · PI CANDELARIO-JALIL, EDUARDO JESUS · 2017 to 2017
$427k
NHLBI NIH HHS T32 HL083810NINDS NIH HHS R01 NS065849NINDS NIH HHS R56 NS103094
6 · The paper itself

Abstract

Activation of the angiotensin II type 2 receptor (AT2R) by administration of Compound 21 (C21), a selective AT2R agonist, induces neuroprotection in models of ischemic stroke in young adult animals. The mechanisms of this neuroprotective action are varied, and may include direct and indirect effects of AT2R activation. Our objectives were to assess the long-term protective effects of post-stroke C21 treatments in a clinically-relevant model of stroke in aged rats and to characterize the cellular localization of AT2Rs in the mouse brain of transgenic reporter mice following stroke. Intraperitoneal injections of C21 (0.03mg/kg) after ischemic stroke induced by transient monofilament middle cerebral artery occlusion resulted in protective effects that were sustained for up to at least 3-weeks post-stroke. These included improved neurological function across multiple assessments and a significant reduction in infarct volume as assessed by magnetic resonance imaging. We also found AT2R expression to be on neurons, not astrocytes or microglia, in normal female and male mouse brains. Stroke did not induce altered cellular localization of AT2R when assessed at 7 and 14 days post-stroke. These findings demonstrate that the neuroprotection previously characterized only during earlier time points using stroke models in young animals is sustained long-term in aged rats, implying even greater clinical relevance for the study of AT2R agonists for the acute treatment of ischemic stroke in human disease. Further, it appears that this sustained neuroprotection is likely due to a mix of both direct and indirect effects stemming from selective activation of AT2Rs on neurons or other cells besides astrocytes and microglia.

Indexed as

AnimalsFemaleMaleMiceNeuroprotective AgentsRatsRats, Sprague-DawleyReceptor, Angiotensin, Type 2StrokeNeuroprotective AgentsReceptor, Angiotensin, Type 2

Identifiers

PMID28671997
PMCPMC5495490
OpenAlexW2731342333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.